作者：赵建清 邢立强 钱海红 李桂林 【摘要】 目的：评价国产新福菌素对老年非小细胞肺癌（NSCLC）的疗效和不良反应。方法：选取老年NSCLC病例81例，随机分治疗组43例给予新福菌素6μg/kg（第1~4d），卡铂（CBP）300mg/m2（第1d），依托泊苷（VP16）100 mg（第1~4或5d）静脉滴注；对照组38例单纯使用CBP和VP16，剂量和方法同治疗组，21~28d为一个疗程，2~3个疗程评价疗效，随访缓解期和生存期。结果：治疗组有效率为5349%，对照组有效率为3158%，差异有显著性（P<005）；中位缓解期分别为6和45个月，中位生存期分别为9和7个月，一年生存率分别为3953%（17/43）和2632%（10/38）。结论：新福菌素联合CBP、VP16治疗老年NSCLC有较好的临床疗效及应用价值。
【关键词】 老年；非小细胞肺癌；化疗；新福菌素；卡铂；依托泊苷
【ABSTRACT】 Objective:To investigate the curative effects and sideeffect of domestic drugSinoactionomycin in treating elderly nonsmall cell lung cancer (NSCLC).Methods: 81 cases with elderly NSCLC were divided into two groups randomly,43 cases in the treatment group were administrated with Sinoactionomycin 6g/kg (1~4 day) combining card platinum (CBP) 300mg/m2 (1st day), glucoside (VP16) 100 mg (1~4 or 5days) intravenously.38 cases in the control group were only treated with CBP and vp16 and the dosage were same with that of treatment group.21~28 days were taken as a treatment cycle and the curative effects were studied after 2~3 cycles.The relievable and survival periods were investigated as well.Results: The effectiveness for treatment troup is 5349%, effectiveness for control group is 3158%, the difference has the significance (P<005); The central relievable period is 6 and 45 months respectively, and the central survival period is 9 and 7 months respectively,on year survival rate respectively is 3953% (17,/43) and 2632% (10,/38). Conclusion: Sinoactionomycin combining CBP,and VP16 has good clinical curative effect in treating elderly NSCLC and has the good clinical practice value.
【KEY WORDS】 Elderly; Nonsmall cell lung cancer; Chemotherapy; Sinoactionomycin; Card platinum; VP16
肺癌一直是男女癌症患者死亡的主要因素[1]。由于非小细胞肺癌（NSCLC）占原发性肺癌的75%~80%，50%以上的NSCLC患者确
[1] [2] 下一页
您现在的位置： 绿色健康网 >> 医学论文 >> 临床医学论文 >> 正文